QuidelOrtho (NASDAQ:QDEL) Issues Earnings Results, Misses Expectations By $0.44 EPS

QuidelOrtho (NASDAQ:QDEL - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.63 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by ($0.44), Zacks reports. QuidelOrtho had a positive return on equity of 4.24% and a negative net margin of 66.25%. QuidelOrtho updated its FY 2025 guidance to 2.070-2.570 EPS.

QuidelOrtho Stock Performance

QDEL traded down $1.08 on Friday, hitting $40.57. The company had a trading volume of 1,445,774 shares, compared to its average volume of 828,934. The company's fifty day moving average price is $43.41 and its 200 day moving average price is $42.39. QuidelOrtho has a 1-year low of $29.74 and a 1-year high of $49.56. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.38 and a quick ratio of 0.81. The stock has a market cap of $2.73 billion, a price-to-earnings ratio of -1.45 and a beta of 0.08.

Insider Buying and Selling

In other news, major shareholder Carlyle Group Inc. sold 8,260,183 shares of the business's stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $35.31, for a total transaction of $291,667,061.73. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Brian J. Blaser purchased 6,033 shares of the stock in a transaction on Wednesday, December 11th. The stock was bought at an average price of $41.42 per share, for a total transaction of $249,886.86. Following the completion of the transaction, the chief executive officer now directly owns 6,033 shares of the company's stock, valued at approximately $249,886.86. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.00% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. UBS Group raised their price objective on QuidelOrtho from $43.00 to $45.00 and gave the stock a "neutral" rating in a research note on Thursday. Royal Bank of Canada cut their price objective on shares of QuidelOrtho from $64.00 to $61.00 and set an "outperform" rating on the stock in a research note on Thursday. Citigroup raised QuidelOrtho from a "neutral" rating to a "buy" rating and lifted their target price for the stock from $44.00 to $50.00 in a report on Wednesday, December 11th. StockNews.com cut QuidelOrtho from a "buy" rating to a "hold" rating in a research note on Saturday. Finally, Jefferies Financial Group started coverage on QuidelOrtho in a research note on Tuesday, December 10th. They issued a "hold" rating and a $43.00 price target on the stock. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, QuidelOrtho currently has a consensus rating of "Hold" and a consensus target price of $51.20.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.